Max Nisen is a Bloomberg Gadfly columnist covering biotech, pharma and health care. He previously wrote about management and corporate strategy for Quartz and Business Insider.

Good morning! This is Fly Charts, the daily charts-only newsletter from Gadfly; sign up here. From IPO doubt to Lands' End misery, here are four charts that tell you what you need to know in business today.

Style Struggle
New leadership and a return to its roots are helping sales at Lands' End. But its long-term outlook is still highly uncertain.
Source: Bloomberg
Revenue Wanted
Don't take Nestle's Atrium purchase as a sign that the company is done contributing to the consumer M&A boom.
Source: Bloomberg
We'll Do it Later
A nascent threat to Botox should raise questions about how Allergan has been spending its rapidly diminishing cash pile.
Source: Bloomberg
A Bit Long in the Tooth
Xiaomi is China's oldest mega-unicorn. But a $50 billion valuation seems like a tough ask as it eyes an IPO.
Source: CB Insights
Note: Chart shows VC-backed companies with $10 billion valuation that have not gone public

And don't miss Tara Lachapelle on Charlie Ergen's mysterious moves: "Deja vu has become a running theme at Dish, between the endless decline of satellite-video subscribers and the repetitious promise of a bright, futuristic vision for Dish's role in the wireless market -- a market in which it's not even a true player yet. This also isn't the first time Ergen has stepped back from his day-to-day CEO responsibilities to pursue grander plans. He did so six years ago and the result was a deal offensive, albeit an unsuccessful one."

This column does not necessarily reflect the opinion of Bloomberg LP and its owners.

To contact the author of this story:
Max Nisen in New York at

To contact the editor responsible for this story:
Mark Gongloff at